Prasad SM, Shishkov D, Mihaylov NV, Genov P, et al. UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial. J Urol 2026 Mar 25:101097JU0000000000005041. doi: 10.1097/JU.0000000000005041.
PMID: 41880645